文献速递免疫规划

MenB-FHbp疫苗在10岁及以上健康人群中临床开发项目的安全性数据

Safety data from the MenB-FHbp clinical development program in healthy individuals aged 10 years and older.
PubMed 文献 · Vaccine · 2022-02-11

该分析汇总了11项已完成试验的安全性数据,其中7项对照试验的局部和全身反应原性数据被合并分析。MenB-FHbp组(n=15294)的局部和全身反应比对照组(n=5509)更频繁,但大多为一过性、轻至中度;两组在IAEs、SAEs、MAEs、NDCMCs及自身免疫或神经炎症事件频率上相似。合并分析未发现新的安全性信号。

要点

  • MenB-FHbp组局部和全身反应较对照组更频繁,但大多为一过性、轻至中度。
  • 两组在IAEs、SAEs、MAEs、NDCMCs及自身免疫或神经炎症事件频率上相似。
  • 合并分析未发现新的安全性信号,继续上市后安全性监测对识别罕见事件重要。

核心结论

  • MenB-FHbp在超过15000名10岁及以上接种者的临床开发项目中表现出良好的安全性和耐受性。
  • 合并分析未发现与单项试验数据相比的新安全性信号。

研究设计与样本

  • 11项试验贡献安全性数据,其中10项记录局部和全身反应原性事件,8项为对照试验,7项对照试验的反应原性数据被合并分析。
  • MenB-FHbp组n=15294,对照组n=5509。

主要发现

  • 局部和全身反应在MenB-FHbp组(n=15294)比对照组(n=5509)更频繁,但大多数反应为一过性、轻至中度。
  • IAEs、SAEs、MAEs、NDCMCs及自身免疫或神经炎症事件的频率在MenB-FHbp组和对照组之间相似。

临床怎么用

  • 原文结论未据此给出具体临床推荐。

局限性

  • 单项临床试验的规模限制了潜在罕见事件的发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The MenB-FHbp vaccine (Trumenba®) is licensed in various countries for the prevention of meningococcal serogroup B disease in individuals ≥ 10 years of age. The clinical development program included 11 completed trials where, in each trial, MenB-FHbp had an acceptable safety profile after a primary vaccination series was administered to individuals 10-65 years of age. However, the detection of potential rare events was limited because of individual clinical trial size. The current safety analysis evaluates pooled reactogenicity and other adverse events (AEs) reported in these trials to identify new safety signals not detectable in individual trials. METHODS: Eleven trials contributed safety data, of which 10 recorded local and systemic reactogenicity events; 8 of the trials were controlled, and reactogenicity data were pooled for 7 of these 8 trials. Additional AE evaluations included immediate AEs (IAEs), medically attended AEs (MAEs), serious AEs (SAEs), newly diagnosed chronic medical conditions (NDCMCs), and autoimmune or neuroinflammatory conditions. RESULTS: Local and systemic reactions were more frequent in the MenB-FHbp group (n = 15,294) compared with controls (n = 5509), although most reactions were transient and mild to moderate in severity. Frequencies of IAEs, SAEs, MAEs, NDCMCs, and autoimmune or neuroinflammatory conditions were similar between the MenB-FHbp and control groups. CONCLUSIONS: MenB-FHbp demonstrated a favorable safety and tolerability profile in the clinical development program of > 15,000 vaccine recipients ≥ 10 years of age. No new safety signals were identified in the pooled analysis compared with data from the individual trials. Continued postmarketing safety surveillance is important for the identification of rare events. Clinicaltrials.gov: NCT01299480; NCT000808028; NCT00879814; NCT00780806; NCT01352845; NCT01352793; NCT01461993; NCT01323270; NCT01830855; NCT01461980; NCT01768117.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Beeslaar J, Mather S, Absalon J, et al. Safety data from the MenB-FHbp clinical development program in healthy individuals aged 10 years and older. Vaccine. 2022. PMID: 35164991. doi:10.1016/j.vaccine.2022.01.046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。